Metabolic dysfunction-associated steatotic liver disease
Conditions
Interventions
The observation group was stratified into four groups (S0, S1, S2, S3) according to hepatic steatosis grading based on MRI-PDFF: Grade 0 (MRI-PDFF 22.1%).:None
Sponsors
China-Japan Union Hospital of Jilin University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Age >= 18 years 2.Patients with type 2 diabetes mellitus 3.Signed informed consent form
Exclusion criteria
Exclusion criteria: 1. Exclusion of specific liver diseases known to cause fatty liver, including alcoholic liver disease, hepatitis C virus genotype 3 infection, autoimmune hepatitis, and Wilson’s disease. 2. Exclusion of special conditions associated with fatty liver, including drug-induced causes (e.g., tamoxifen, amiodarone, valproate sodium, methotrexate, glucocorticoids), total parenteral nutrition, inflammatory bowel disease, celiac disease, hypothyroidism, Cushing’s syndrome, ß-lipoprotein deficiency, lipodystrophic diabetes, and Mauriac syndrome. 3. Exclusion of acute or chronic kidney disease and renal failure. 4. Exclusion of patients with prior cholecystectomy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Attenuation coefficient;Magnetic Resonance Imaging Proton Density Fat Fraction;Controlled Attenuation Parameter; | — |
Secondary
| Measure | Time frame |
|---|---|
| Demographic characteristics (including sex, age, height, weight, body mass index, waist circumference, hip circumference, and history of diabetes).; | — |
Countries
China
Contacts
Public ContactSun Zhixia
China-Japan Union Hospital of Jilin University
Outcome results
None listed